Who Paid My Doc
Elsayed Mohamed
Interventional Cardiology Schaumburg, IL Medical Doctor
NPI 1841484813 CMS profile 38688
804 E Woodfield Rd Ste 300, 808 E Woodfield Road Suite 100, Schaumburg, IL 60173
General payments
$14,708
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Elsayed Mohamed of Schaumburg, IL is reported in the CMS Open Payments database as having received $14,708 across 154 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 68th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,747 | 23 | |
| 2024 | General | $2,365 | 45 | |
| 2023 | General | $4,711 | 18 | |
| 2022 | General | $685 | 10 | |
| 2021 | General | $763 | 20 | |
| 2020 | General | $258 | 7 | |
| 2019 | General | $4,178 | 31 |
Beside peers
- Elsayed Mohamed
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Elsayed Mohamed were reported at $1,747. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Elsayed Mohamed | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,178 | $1,097 | $329–$3,048 | $163 |
| 2020 | $258 | $473 | $161–$1,480 | $114 |
| 2021 | $763 | $677 | $233–$1,827 | $132 |
| 2022 | $685 | $978 | $333–$2,724 | $149 |
| 2023 | $4,711 | $1,136 | $382–$2,986 | $160 |
| 2024 | $2,365 | $1,181 | $395–$3,326 | $164 |
| 2025 | $1,747 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 33 drugsPart D claims
2,621
Drug cost
$280,204
Branded share of claims
21.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 57 | $71,202 | |
| Jardiance Empagliflozin | Brand | 53 | $62,220 | |
| Xarelto Rivaroxaban | Brand | 35 | $49,357 | |
| Entresto Sacubitril/Valsartan | Brand | 45 | $41,735 | |
| Brilinta Ticagrelor | Brand | 23 | $19,592 | |
| Vascepa Icosapent Ethyl | Brand | 11 | $6,765 | |
| Rosuvastatin Calcium | Generic | 193 | $4,084 | |
| Metoprolol Succinate | Generic | 206 | $3,281 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 278 | $2,784 | |
| Ezetimibe | Generic | 92 | $2,449 |
The 10 drugs with the highest cost, of 33 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 133 billing codesPaid by Medicare
$849,950
Medicare patients
1,023
Services billed
31,198
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 75% | |
| Arthritis | 49% | |
| Diabetes | 45% | |
| Heart failure | 43% | |
| Atrial fibrillation | 41% | |
| Chronic kidney disease | 36% | |
| COPD | 22% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 272 | 26,187 | $2,713 |
| Injection, regadenoson, 0.1 mg J2785 | Office | 108 | 430 | $2,623 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
154 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in Illinois
Andrei Pop
Interventional Cardiology · Elk Grove Village, IL
Atman Shah
Interventional Cardiology · Chicago, IL
Ravi Ramana
Interventional Cardiology · Palos Park, IL
Mahesh Raju
Interventional Cardiology · Downers Grove, IL
Mark Ricciardi
Interventional Cardiology · Evanston, IL
Neal Sawlani
Interventional Cardiology · Park Ridge, IL
Related records
Interventional Cardiology in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.